On November 15, 2019 Skyhawk reported its fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve (Press release, Skyhawk Therapeutics, NOV 15, 2019, View Source [SID1234626570]). Skyhawk partnered with Celgene to discover and develop small molecules for autoimmune disease and cancer against hard-to-drug targets that have been clinically validated, or genetically associated with a disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Skyhawk Therapeutics Inc. uses its SkySTAR platform to discover and develop small molecules capable of modulating RNA splicing within the spliceosome, dictating which exons are included in the final mRNA transcript and offering drug developers a mechanism to control protein expression at the level of mRNA. The therapeutic approach can be applied broadly to indications where attempts at drugging a target at the protein level have been unsuccessful (see "Splice Time")